

Supplementary Material

*nor*Ursodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis

Peter Fickert¹, Gideon M. Hirschfield², Gerald Denk³, Hanns-Ulrich Marschall⁴, Istvan Altorjay⁵, Martti Färkkilä⁶, Christoph Schramm⁷, Ulrich Spengler⁸, Roger Chapman⁹, Annika Bergquist¹⁰, Erik Schrumpf¹¹, Frederik Nevens¹², Palak Trivedi², Florian P. Reiter³, Istvan Tornai⁵, Emina Halilbasic¹³, Roland Greinwald¹⁴, Markus Pröls¹⁴, Michael P. Manns¹⁵, and Michael Trauner^{13*} for the European PSC *nor*UDCA Study Group

¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz Austria; ²Centre for Liver Research and NIHR Biomedical Research Unit, University of Birmingham, United Kingdom; ³Department of Medicine II, Liver Center Munich, Ludwig Maximilians University (LMU), Munich, Germany; ⁴Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden; ⁵Department of Gastroenterology, School of Medicine, Debrecen University, Debrecen, Hungary; ⁶University of Helsinki and Clinic of Gastroenterology, Helsinki University Hospital, Helsinki, Finland; ⁷1st Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ⁸Department of Internal Medicine 1, Rheinische Friedrich-Wilhelm's University Bonn, Bonn, Germany; ⁹Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, United Kingdom; ¹⁰Department of Gastroenterology and Hepatology, Karolinska University Hospital, Karolinska Institute, Huddinge, Stockholm, Sweden; ¹¹Section of Gastroenterology, Department of Transplantation Medicine, Division of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ¹²Hepatology, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium; ¹³Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; ¹⁴Dr. Falk Pharma GmbH, Freiburg, Germany; ¹⁵Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany .

*Correspondence: Michael Trauner, MD, Email: michael.trauner@meduniwien.ac.at

Table of Content

Supplementary Table 1..... 3
Supplementary Figure 1 3
Supplementary Table 2..... 4

Supplementary Table 1. Number and percentage of patients receiving UDCA during the follow-up phase *

UDCA during follow-up phase	Placebo (N=40)	<i>nor</i> UDCA 500mg (N=39)	<i>nor</i> UDCA 1000mg (N=41)	<i>nor</i> UDCA 1500mg (N=39)
No	31 (77.5%)	35 (89.7%)	39 (95.1%)	34 (87.2%)
Yes	9 (22.5%)	4 (10.3%)	2 (4.9%)	5 (12.8%)

*i.e. start date of UDCA treatment from visit 8/EOT date onwards.

Supplementary Figure 1




Figure legend. Patients' percentage without therapeutic response to *nor*UDCA. Nonresponse was defined as ALP at EOT above ALP values at screening (when most patients were still on UDCA). As sharp decline in the percentage of patients lacking a response to *nor*UDCA was observed with increasing *nor*UDCA dose in previous UDCA responders, UDCA non-responders and – most pronounced – in UDCA naïve patients.

Supplementary Table 2. Total bilirubin [mg/dl] at baseline and EOT, and absolute and relative change from baseline to EOT

	Total bilirubin [mg/dl]			Absolute change from baseline [mg/dl]			Relative change from baseline [%]		
	n	Mean	Median	n	Mean	Median	n	Mean	Median
Baseline									
Placebo	40	0.91	0.86	---	---	---	---	---	---
<i>nor</i> UDCA 500 mg	39	1.13	0.95	---	---	---	---	---	---
<i>nor</i> UDCA 1000 mg	41	0.94	0.82	---	---	---	---	---	---
<i>nor</i> UDCA 1500 mg	39	1.05	0.86	---	---	---	---	---	---
EOT (LOCF)									
Placebo	40	1.09	0.85	40	0.18	0.01	40	23.2	1.9
<i>nor</i> UDCA 500 mg	39	1.24	0.99	39	0.10	0.00	39	10.8	0.0
<i>nor</i> UDCA 1000 mg	41	1.03	0.80	41	0.08	0.04	41	11.1	6.8
<i>nor</i> UDCA 1500 mg	39	0.96	0.84	39	-0.09	-0.04	39	2.5	-7.1
Week 12									
Placebo	36	0.97	0.83	36	0.06	0.01	36	13.5	1.9
<i>nor</i> UDCA 500 mg	29	1.27	1.05	29	0.16	0.02	29	14.4	2.8
<i>nor</i> UDCA 1000 mg	37	1.00	0.82	37	0.07	0.05	37	11.7	6.8
<i>nor</i> UDCA 1500 mg	36	0.91	0.84	36	-0.12	-0.05	36	-0.4	-7.6